Entera Bio Ltd. announced that it has entered into a securities purchase agreement to issue 7,916,879 units at a price of $0.835 per unit for the gross proceeds of $6,610,594 on December 20, 2023. Each unit will consist of one common share and one share purchase warrant. Each ordinary share warrant has an exercise price of $1.00 per share and is immediately exercisable, and expires five years from the date of issuance, and is subject to customary adjustments.

The transaction included participation from individual investors, Miranda Toledano, the company?s Chief Executive Officer, and Gerald Lieberman, chairman of the company?s board of directors and other investor. As a part of the transaction, the company paid a customary cash placement fee to the placement agent and (ii) issue to the Placement Agent (or its designees) warrants to purchase up to 487,496 Ordinary Shares, pay a non-U.S. individual (the ? Finder ?) a customary cash finder fee and (ii) issue to the Finder warrants (the ?

Finder Warrants ?) to purchase up to 179,640 Ordinary Shares.